catechin has been researched along with Dyslipidemia in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Fraga, CG; Galleano, M; Hid, EJ; Mosele, JI; Prince, PD | 1 |
| Cremonini, E; Iglesias, DE; Kang, J; Lombardo, GE; Mostofinejad, Z; Oteiza, PI; Wang, Z; Zhu, W | 1 |
| Jian, JY; Lin, CH; Shih, CC; Wu, JB | 1 |
| Fang, B; Guan, S; Huang, Y; Jin, Y; Lu, J; Sun, B; Tao, S | 1 |
| Li, W; Zhang, K; Zhao, Q | 1 |
| An, Y; Chang, Y; Cheng, J; Dang, H; Feng, J; Guo, H; Luo, K; Ma, C; Qiao, L; Shao, H; Tian, J; Xie, L; Xing, W; Yang, J; Yuan, Y | 1 |
| Miltonprabu, S; Thangapandiyan, S | 1 |
| Kim, JA | 1 |
| Baraghis, E; Bolduc, V; Duquette, N; Lambert, J; Lesage, F; Thorin, E; Thorin-Trescases, N | 1 |
3 review(s) available for catechin and Dyslipidemia
| Article | Year |
|---|---|
( -)-Epicatechin and cardiometabolic risk factors: a focus on potential mechanisms of action.
Topics: Animals; Cardiometabolic Risk Factors; Catechin; Dyslipidemias; Humans; Hyperglycemia; Hypertension; Obesity | 2022 |
(-)-Epicatechin and the comorbidities of obesity.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Catechin; Comorbidity; Diabetes Mellitus, Type 2; Dysbiosis; Dyslipidemias; Endoplasmic Reticulum; Endotoxins; Flavonoids; Humans; Inflammation; Insulin Resistance; Lipid Metabolism; Mental Disorders; Mitochondria; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress | 2020 |
Mechanisms underlying beneficial health effects of tea catechins to improve insulin resistance and endothelial dysfunction.
Topics: Animals; Catechin; Dyslipidemias; Endothelium, Vascular; Glucose; Humans; Insulin Resistance; Obesity; Tea; Vascular Diseases | 2008 |
6 other study(ies) available for catechin and Dyslipidemia
| Article | Year |
|---|---|
(-)-Epicatechin-3-O-β-D-allopyranoside from Davallia formosana prevents diabetes and dyslipidemia in streptozotocin-induced diabetic mice.
Topics: Animals; Catechin; Diabetes Mellitus, Experimental; Dyslipidemias; Ferns; Glycosides; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Rhizome | 2017 |
Epigallocatechin-3-gallate protects against 1,3-dichloro-2-propanol-induced lipid accumulation in C57BL/6J mice.
Topics: alpha-Chlorohydrin; Animals; Antioxidants; Catechin; Dyslipidemias; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Mutagens; Protective Agents | 2018 |
Fructooligosaccharide enhanced absorption and anti-dyslipidemia capacity of tea flavonoids in high sucrose-fed mice.
Topics: Animals; Antioxidants; Catechin; Cholesterol; Chromatography, Liquid; Dietary Sucrose; Dyslipidemias; Fatty Acids; Flavonoids; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Male; Mice; Oligosaccharides; Tandem Mass Spectrometry; Tea; Triglycerides | 2019 |
Caffeine-free hawk tea lowers cholesterol by reducing free cholesterol uptake and the production of very-low-density lipoprotein.
Topics: Animals; Anticholesteremic Agents; Biological Transport, Active; Caffeine; Catechin; Cholesterol; Disease Models, Animal; Dyslipidemias; Feeder Cells; Gastrointestinal Microbiome; Hep G2 Cells; Humans; Kaempferols; Lipid Metabolism; Lipoproteins, VLDL; Litsea; Liver; Male; Models, Biological; Quercetin; Rats; Rats, Sprague-Dawley; Receptors, LDL; Sterol Regulatory Element Binding Protein 2; Teas, Medicinal | 2019 |
Epigallocatechin gallate potentially attenuates Fluoride induced oxidative stress mediated cardiotoxicity and dyslipidemia in rats.
Topics: Adenosine Triphosphatases; Animals; Antioxidants; Biomarkers; Body Weight; Calcium; Cardiotoxicity; Catechin; DNA Fragmentation; Drinking Behavior; Dyslipidemias; Feeding Behavior; Fluorides; Lipid Peroxidation; Lipids; Male; Membranes; Mitochondria, Heart; Myocardium; Organ Size; Oxidative Stress; Rats; Rats, Wistar | 2015 |
Catechin prevents severe dyslipidemia-associated changes in wall biomechanics of cerebral arteries in LDLr-/-:hApoB+/+ mice and improves cerebral blood flow.
Topics: Animals; Antioxidants; Apolipoproteins B; Biomechanical Phenomena; Catechin; Cerebral Arteries; Cerebrovascular Circulation; Compliance; Disease Models, Animal; Dyslipidemias; Endothelium, Vascular; Enzyme Precursors; Genotype; Humans; Intracranial Arteriosclerosis; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Phenotype; Receptors, LDL; Severity of Illness Index; Stress, Mechanical; Tomography, Optical Coherence; Vasodilation | 2012 |